PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - McMurray, John
TI  - Angiotensin-Neprilysin Inhibitor Could Become a New Standard for HF
DP  - 2014  01
TA  - MD Conference Express
PG  - 8--9
VI  - 14
IP  - 42
4099  - http://mdc.sagepub.com/content/14/42/8.short
4100  - http://mdc.sagepub.com/content/14/42/8.full
AB  - Clinical outcomes, including mortality, are improved with the use of a dual angiotensin receptor blocker-neprilysin inhibitor (ARNI), LCZ696, compared with the existing gold standard in the treatment of patients with chronic heart failure (CHF). iscussed findings and insights from a study that evaluated the efficacy and safety of LCZ696 vs enalapril on the morbidity and mortality of patients with CHF-namely, the PARADIGM-HF trial.